Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Creo Medical ( (GB:CREO) ).
Creo Medical Group plc has announced a Capital Markets Day event for investors and analysts to be held on 19 November 2025 in London. This event underscores the company’s commitment to engaging with stakeholders and highlights its focus on the growing field of minimally invasive surgical endoscopy, potentially impacting its market position and stakeholder relations.
The most recent analyst rating on (GB:CREO) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.
Spark’s Take on GB:CREO Stock
According to Spark, TipRanks’ AI Analyst, GB:CREO is a Neutral.
Creo Medical’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, while valuation metrics are poor due to negative earnings. These factors collectively contribute to a low overall score.
To see Spark’s full report on GB:CREO stock, click here.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on enhancing surgical capabilities and patient outcomes through its advanced CROMA technology powered by Kamaptive, which integrates multi-modal energy sources for procedures such as resection, dissection, coagulation, and ablation.
Average Trading Volume: 613,126
Technical Sentiment Signal: Strong Sell
Current Market Cap: £45.37M
For detailed information about CREO stock, go to TipRanks’ Stock Analysis page.